Skip to main content
DEINOVE logo

DEINOVE — Investor Relations & Filings

Ticker · ALDEI ISIN · FR0010879056 LEI · 969500BEJSRFER0F2K08 PA Professional, scientific and technical activities
Open in API
Filings indexed 300 across all filing types
Latest filing 2017-01-23 Board/Management Inform…
Country FR France
Listing PA ALDEI

About DEINOVE

https://www.deinove.com

DEINOVE is a biotechnology company that discovers, develops, and produces high-value compounds derived from rare bacteria and microorganisms, often referred to as 'microbial dark matter'. Leveraging a proprietary technology platform, the company harnesses the metabolic potential of extremophilic bacteria, such as Deinococcus, to create innovative solutions. Its primary applications are focused on developing novel bio-based active ingredients, including carotenoids, for the cosmetics sector, and discovering new antibiotics to address the global challenge of antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 1% confidence The document is explicitly titled "Press release" and announces significant changes in the company's Board of Directors, including the appointment of new directors and a new Chairman. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is not a full annual report (10-K), an earnings release (ER), or a transcript (CT).
2017-01-23 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "DEINOVE ANNONCE SON CALENDRIER FINANCIER 2017" (DEINOVE Announces its 2017 Financial Calendar). It explicitly lists future dates for key corporate events: Annual Results publication (March 30), Annual General Meeting (May 16), and Semi-annual Results publication (September 28). This document is not the actual financial report (10-K or IR) or the AGM presentation (AGM-R), but rather an announcement detailing *when* these reports and meetings will occur. According to Rule 2, a short announcement about the timing/publication of reports points towards a Report Publication Announcement (RPA).
2017-01-11 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is titled "DEINOVE ANNOUNCES ITS FINANCIAL CALENDAR FOR 2017" and explicitly lists future dates for key corporate events, including the 'Publication of 2016 Annual Results', 'Annual Shareholders Meeting', and 'Publication of 2017 First Half Financial Results'. This document is an announcement about the schedule of future corporate reports and meetings, not the reports themselves. Since it announces the timing of report publications and shareholder meetings, it fits best under the category for announcing report publication timing, which is Report Publication Announcement (RPA). It is too specific for the general Regulatory Filings (RNS) fallback, and it is not the actual AGM material (AGM-R) or the actual financial results (10-K, IR, ER). The document length (2045 chars) is short, supporting the 'announcement' classification over the full report classification.
2017-01-11 English
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 1% confidence The document announces the completion of a 'contribution in kind' transaction where DEINOVE acquired 100% of its subsidiary DEINOBIOTICS, involving a share capital increase. It also mentions the approval of terms by an 'Extraordinary General Meeting' held on January 5, 2017. While it mentions a General Meeting, the core content is about a significant corporate financing/capital structure change (issuing new shares to complete the acquisition) and the resulting capital increase. This aligns best with the 'Capital/Financing Update' (CAP) category, as it details the issuance of 1,001,437 new shares and the resulting dilution, which is a direct capital structure change resulting from a transaction. It is not a standard earnings release (ER), interim report (IR), or a general AGM presentation (AGM-R).
2017-01-05 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and details the completion of a corporate transaction: DEINOVE acquiring 100% of its subsidiary DEINOBIOTICS through an in-kind contribution ('apport en nature') followed by a corresponding capital increase. This announcement concerns financing activities, capital structure changes (issuance of new shares), and a significant corporate transaction (acquisition/consolidation of a subsidiary). While it touches upon capital changes (CAP) and potentially M&A (TAR), the core focus is the execution of a financing/capital restructuring event resulting from the acquisition. The issuance of new shares to compensate the contributors strongly aligns with the 'Capital/Financing Update' definition (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific, material corporate action related to capital structure.
2017-01-05 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces the publication of patent applications related to a novel antibiotic candidate and preparation for preclinical studies. It discusses intellectual property (IP) development and future research pipeline. This type of announcement, focusing on R&D milestones, IP protection, and general company updates rather than specific financial results (ER, IR), management changes (MANG), or shareholder votes (DVA), fits best under a general regulatory or corporate announcement category. Since it is a press release announcing a significant R&D/IP step, and it doesn't fit perfectly into the more specific categories like CAP (financing), LTR (legal), or MANG, the most appropriate classification is the general regulatory/miscellaneous filing category, RNS (Regulatory Filings), as it is a formal communication to the market about a corporate development that isn't strictly financial reporting or governance. The length (4290 chars) is substantial enough that it is the report itself, not just an announcement of a report (RPA).
2017-01-04 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.